[go: up one dir, main page]

MA52632A - Anticorps bispécifiques bcma/cd3 et gprdc5d/cd3 aux fins d'utilisation dans le traitement du cancer - Google Patents

Anticorps bispécifiques bcma/cd3 et gprdc5d/cd3 aux fins d'utilisation dans le traitement du cancer

Info

Publication number
MA52632A
MA52632A MA052632A MA52632A MA52632A MA 52632 A MA52632 A MA 52632A MA 052632 A MA052632 A MA 052632A MA 52632 A MA52632 A MA 52632A MA 52632 A MA52632 A MA 52632A
Authority
MA
Morocco
Prior art keywords
gprdc5d
bcma
cancer
treatment
bispecific antibodies
Prior art date
Application number
MA052632A
Other languages
English (en)
Inventor
Homer Adams
Kris Frerichs
Francois Gaudet
De Donk Niels Van
Christie Verkleij
Original Assignee
Janssen Biotech Inc
Stichting Vumc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc, Stichting Vumc filed Critical Janssen Biotech Inc
Publication of MA52632A publication Critical patent/MA52632A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA052632A 2018-05-16 2019-05-15 Anticorps bispécifiques bcma/cd3 et gprdc5d/cd3 aux fins d'utilisation dans le traitement du cancer MA52632A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862672222P 2018-05-16 2018-05-16
US201862736804P 2018-09-26 2018-09-26
US201962842080P 2019-05-02 2019-05-02

Publications (1)

Publication Number Publication Date
MA52632A true MA52632A (fr) 2021-09-15

Family

ID=67253932

Family Applications (2)

Application Number Title Priority Date Filing Date
MA052632A MA52632A (fr) 2018-05-16 2019-05-15 Anticorps bispécifiques bcma/cd3 et gprdc5d/cd3 aux fins d'utilisation dans le traitement du cancer
MA052640A MA52640A (fr) 2018-05-16 2019-05-15 Procédés de traitement de cancers et d'amélioration de l'efficacité d'agents thérapeutiques de redirection de lymphocytes t

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA052640A MA52640A (fr) 2018-05-16 2019-05-15 Procédés de traitement de cancers et d'amélioration de l'efficacité d'agents thérapeutiques de redirection de lymphocytes t

Country Status (20)

Country Link
US (4) US12012461B2 (fr)
EP (2) EP3793599A1 (fr)
JP (4) JP7395508B2 (fr)
KR (2) KR20210011002A (fr)
CN (3) CN112368019B (fr)
AU (4) AU2019270624B2 (fr)
BR (2) BR112020023187A2 (fr)
CA (2) CA3100118A1 (fr)
CL (3) CL2020002945A1 (fr)
DO (1) DOP2020000209A (fr)
IL (2) IL278667B1 (fr)
JO (1) JOP20200292A1 (fr)
MA (2) MA52632A (fr)
MX (5) MX2020012286A (fr)
MY (2) MY205856A (fr)
PH (2) PH12020551908A1 (fr)
SG (2) SG11202010977QA (fr)
TW (2) TW202430571A (fr)
UY (2) UY38235A (fr)
WO (2) WO2019220369A2 (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2647707T (lt) 2010-11-30 2018-11-12 Chugai Seiyaku Kabushiki Kaisha Citotoksiškumą indukuojantis terapinis agentas
US11851476B2 (en) 2011-10-31 2023-12-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
MX380176B (es) 2014-04-07 2025-03-12 Chugai Pharmaceutical Co Ltd Molecula ligada a antigeno inmunoactivada.
US11505605B2 (en) 2014-05-13 2022-11-22 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
EP3227338A4 (fr) 2014-12-04 2018-05-16 Janssen Biotech, Inc. Anticorps anti-cd38 pour le traitement de la leucémie aiguë myéloïde
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
KR102537102B1 (ko) 2015-05-29 2023-05-25 엠피베나 테라퓨틱스, 인크. 이중특이적 cd33 및 cd3 결합 단백질을 사용하는 방법
PL3827845T3 (pl) * 2015-11-03 2022-07-11 Janssen Biotech, Inc. Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
EP3378488A4 (fr) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha Procédé pour renforcer la réponse immunitaire humorale
JP7219005B2 (ja) 2015-12-28 2023-02-07 中外製薬株式会社 Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
EP3431102A4 (fr) 2016-03-14 2019-09-25 Chugai Seiyaku Kabushiki Kaisha Médicament thérapeutique induisant des lésions cellulaires à utiliser dans le traitement du cancer
IL267485B2 (en) 2016-12-21 2024-01-01 Teneobio Inc Anti-bcma heavy chain-only antibodies and uses thereof
EP3824906A1 (fr) 2016-12-21 2021-05-26 Amgen Inc. Formulations d'anticorps anti-tnf alpha
AU2019270624B2 (en) 2018-05-16 2024-05-02 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
RS66901B1 (sr) * 2018-05-24 2025-07-31 Janssen Biotech Inc Anti-cd3 antitela i njihova upotreba
JOP20200303A1 (ar) * 2018-05-24 2020-11-23 Janssen Biotech Inc عوامل ربط psma واستخداماتها
EA202092849A1 (ru) * 2018-05-24 2021-03-16 Янссен Байотек, Инк. Моноспецифические и мультиспецифические антитела к tmeff2 и их применение
KR20220002899A (ko) * 2019-04-19 2022-01-07 얀센 바이오테크 인코포레이티드 항-psma/cd3 항체로 전립선암을 치료하는 방법
EP3733707A1 (fr) * 2019-04-30 2020-11-04 Celyad S.A. Cellules car-t de ciblage de bcma et leurs utilisations
KR102503349B1 (ko) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
PE20220394A1 (es) * 2019-07-31 2022-03-18 Hoffmann La Roche Anticuerpos que se fijan a gprc5d
MX2022001711A (es) * 2019-08-09 2022-05-10 A2 Biotherapeutics Inc Receptores en la superficie celular que responden a la perdida de heterocigosidad.
TWI774137B (zh) * 2019-11-26 2022-08-11 大陸商上海岸邁生物科技有限公司 針對cd3和bcma的抗體和自其製備的雙特異性結合蛋白
IL296358A (en) * 2020-03-13 2022-11-01 Janssen Biotech Inc Materials and methods for modulating delta chain mediated immunity
IL298046A (en) 2020-05-11 2023-01-01 Janssen Biotech Inc Methods for treating multiple myeloma
MX2022014180A (es) * 2020-05-13 2022-12-02 Pfizer Metodos, terapias y usos para tratar cancer.
MX2022014426A (es) * 2020-05-19 2023-04-21 Janssen Biotech Inc Composiciones que comprenden una terapéutica de redirección de células t y un inhibidor de la ruta de adhesión de vla-4.
GB2595299B (en) * 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
KR20230017841A (ko) 2020-05-27 2023-02-06 얀센 바이오테크 인코포레이티드 Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
IL297566B2 (en) * 2020-06-01 2024-07-01 Mustbio Co Ltd Bispecific antibody or antigen-binding fragment thereof, and preparation method therefor
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
BR112023004830A2 (pt) * 2020-09-16 2023-04-18 Janssen Biotech Inc Métodos para tratamento de mieloma múltiplo
TW202233672A (zh) * 2020-10-22 2022-09-01 美商健生生物科技公司 包括類δ配體３（ＤＬＬ３）抗原結合區之蛋白質及其用途
KR20230090367A (ko) 2020-11-04 2023-06-21 주노 쎄러퓨티크스 인코퍼레이티드 변형된 불변 cd3 이뮤노글로불린 슈퍼패밀리 쇄 유전자좌로부터 키메라 수용체를 발현하는 세포 및 관련 폴리뉴클레오티드 및 방법
HRP20250696T1 (hr) 2021-01-28 2025-08-01 Regeneron Pharmaceuticals, Inc. Sastavi i postupci za liječenje sindroma oslobađanja citokina
US20220267438A1 (en) * 2021-02-16 2022-08-25 Janssen Pharmaceutica Nv Trispecific antibody targeting bcma, gprc5d, and cd3
US20250074996A1 (en) * 2021-02-19 2025-03-06 Innovent Biologics (Suzhou) Co., Ltd. ANTI-GPRC5DxBCMAxCD3 TRISPECIFIC ANTIBODY AND USE THEREOF
AU2022278013A1 (en) * 2021-05-18 2024-01-18 Janssen Biotech, Inc. Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic
KR20240014482A (ko) * 2021-05-28 2024-02-01 얀센 바이오테크 인코포레이티드 B 세포 림프종에서 T 세포 재지향 항체에 대한 표적으로서의 Bcma
CN119569887A (zh) * 2021-06-24 2025-03-07 益科思特(北京)医药科技发展有限公司 结合bcma和cd3的双特异性抗体及其制备方法与应用
TW202325743A (zh) * 2021-07-14 2023-07-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｃｄ３８、ｂｃｍａ和ｃｄ３的抗原結合分子及其醫藥用途
CN118369114A (zh) * 2021-11-03 2024-07-19 詹森生物科技公司 治疗癌症并增强GPRC5DxCD3双特异性抗体的功效的方法
AU2022380722A1 (en) * 2021-11-03 2024-06-20 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
AU2022383848A1 (en) * 2021-11-10 2024-06-27 Janssen Biotech, Inc. Stable formulations comprising a bispecific bcma/cd3 antibody
WO2023201226A1 (fr) 2022-04-11 2023-10-19 Regeneron Pharmaceuticals, Inc. Compositions et méthodes permettant la destruction de cellule tumorale universelle
WO2023227062A1 (fr) * 2022-05-27 2023-11-30 Antengene (Hangzhou) Biologics Co., Ltd. Nouveaux anticorps anti-gprc5d, molécules de liaison à l'antigène bispécifiques qui se lient à gprc5d et cd3, et leurs utilisations
CN114807358B (zh) * 2022-05-30 2023-02-28 北京体育大学 一种与肌腱损伤相关的生物标志物
JP2025522351A (ja) 2022-06-06 2025-07-15 山▲東▼先声生物制▲薬▼有限公司 Ｂｃｍａ、ｇｐｒｃ５ｄ及びｔ細胞を標的とする多重特異性抗体並びにその応用
CA3266816A1 (fr) * 2022-09-09 2024-03-14 Janssen Biotech Inc Méthode de traitement du cancer avec un anticorps bispécifique anti-tmeff2xcd3
CN117924485A (zh) * 2022-10-25 2024-04-26 上海祥耀生物科技有限责任公司 一种抗gprc5d的多特异性抗体
WO2024102954A1 (fr) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Système d'écrêtage induit par activation (aics)
AU2023404602A1 (en) 2022-11-29 2025-05-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Cldn18.2/4-1bb binding protein and medical use thereof
WO2024146458A1 (fr) * 2023-01-06 2024-07-11 广东东阳光药业股份有限公司 Anticorps humanisé anti-cytokine il-11
TW202434644A (zh) 2023-02-07 2024-09-01 大陸商上海齊魯製藥研究中心有限公司 三特異性抗原結合分子及其應用
KR20250151441A (ko) 2023-02-17 2025-10-21 리제너론 파마슈티칼스 인코포레이티드 Cd3/taa 이중특이적 항체에 대해 반응성인 유도된 nk 세포
WO2024220516A2 (fr) * 2023-04-18 2024-10-24 Hackensack Meridian Health, Inc. Procédés d'immunothérapie ciblée contre la leucémie myéloïde aiguë (aml)
AU2024257950A1 (en) * 2023-04-19 2025-12-04 Janssen Biotech, Inc. Methods for treating multiple myeloma
US20250242019A2 (en) * 2023-04-19 2025-07-31 Janssen Biotech, Inc. Methods for treating multiple myeloma
CA3205511A1 (en) * 2023-04-19 2025-03-17 Janssen Biotech Inc Bcma-targeted car-t cell therapy for multiple myeloma
WO2025059362A1 (fr) * 2023-09-13 2025-03-20 Juno Therapeutics, Inc. Polythérapies comprenant une thérapie cellulaire exprimant un car ciblant gprc5d, méthodes et utilisations associés
WO2025096717A1 (fr) 2023-11-01 2025-05-08 Janssen Biotech, Inc. Méthodes de traitement du myélome multiple
WO2025094107A1 (fr) 2023-11-01 2025-05-08 Janssen Biotech, Inc. Méthodes de traitement du myélome multiple indolent à haut risque
WO2025229159A1 (fr) * 2024-05-01 2025-11-06 Commit Biologics Aps Anticorps et constructions d'anticorps dirigés contre cd20
WO2025243241A1 (fr) 2024-05-23 2025-11-27 Janssen Biotech, Inc. Méthodes de traitement d'un myélome multiple

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
EP0672142B1 (fr) 1992-12-04 2001-02-28 Medical Research Council Proteines de liaison multivalentes et multispecifiques, leur fabrication et leur utilisation
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
DE69841578D1 (de) 1997-09-16 2010-05-06 Centocor Inc Methoden zur kompletten chemischen Synthese und Zusammensetzung von Genen und Genomen
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2001024812A1 (fr) 1999-10-06 2001-04-12 N.V. Nutricia UTILISATION DU FACTEUR DE CROISSANCE TRANSFORMANT β ET DE FACTEURS DE CROISSANCE POUR LE TRAITEMENT ET LA PREVENTION D'UNE MALADIE DE LA MUQUEUSE INTESTINALE
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
WO2002066516A2 (fr) 2001-02-20 2002-08-29 Zymogenetics, Inc. Anticorps liant a la fois bcma et taci
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
CA2517145C (fr) 2003-03-05 2017-08-01 Halozyme, Inc. Glycoproteine hyaluronidase soluble (shasegp), procede de fabrication et compositions pharmaceutiques contenant ladite proteine
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
CA2577082A1 (fr) 2004-09-02 2006-03-16 Genentech, Inc. Molecules heteromultimeriques
EA015584B1 (ru) 2005-03-23 2011-10-31 Генмаб А/С Антитело к cd38 человека и его применение
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
ES2856451T3 (es) 2005-10-11 2021-09-27 Amgen Res Munich Gmbh Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas
JP5362359B2 (ja) 2005-10-12 2013-12-11 モルフォシス アーゲー ヒトＣＤ３８に特異的な完全ヒトＨｕＣＡＬＧＯＬＤ由来の治療抗体の生成とプロファイリング
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
WO2007110205A2 (fr) 2006-03-24 2007-10-04 Merck Patent Gmbh Domaines de proteine heterodimerique d'ingenierie
WO2007117600A2 (fr) 2006-04-07 2007-10-18 Macrogenics, Inc. Polythérapie pour le traitement de maladies autoimmunes
WO2007147901A1 (fr) 2006-06-22 2007-12-27 Novo Nordisk A/S Production d'anticorps bispécifiques
HRP20191115T1 (hr) * 2006-09-26 2019-09-20 Genmab A/S Anti-cd38 u kombinaciji s kortikosteroidima zajedno s jednim ne-kortikosteroidnim kemoterapeutikom za liječenje tumora
EP1914242A1 (fr) 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer
AU2008234019B2 (en) 2007-04-03 2014-05-29 Amgen Research (Munich) Gmbh Cross-species-specific bispecific binders
KR101589759B1 (ko) 2007-04-03 2016-01-29 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 ｃｄ３―입실론 결합 도메인
PT2155783E (pt) 2007-04-03 2013-11-07 Amgen Res Munich Gmbh Domínio de ligação específico inter-espécies
ES2564523T3 (es) 2007-12-19 2016-03-23 Janssen Biotech, Inc. Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos
EP2283355A2 (fr) 2008-04-25 2011-02-16 Zymogenetics, Inc. Niveaux d expression de la protéine bcma sur les lymphocytes b et utilisation dans de méthodes diagnostiques
CN102076355B (zh) 2008-04-29 2014-05-07 Abbvie公司 双重可变结构域免疫球蛋白及其用途
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
BRPI0919841A2 (pt) 2008-10-01 2014-11-18 Micromet Ag Anticorpo de cadeia unica biespecifico de psmaxcd3, especifico de especies cruzadas
EP2352763B2 (fr) 2008-10-01 2022-09-21 Amgen Research (Munich) GmbH Anticorps monocaténaires bispécifiques spécifiques d'antigènes cibles de masse moléculaire élevée
CN102307896B (zh) 2008-10-31 2016-10-12 森托科尔奥索生物科技公司 基于iii型纤连蛋白结构域的支架组合物、方法及用途
CA2752211C (fr) 2009-02-12 2020-03-24 Janssen Biotech, Inc. Compositions supports a base du domaine de la fibronectine de type iii, procedes et utilisations
HRP20161194T1 (hr) 2009-03-10 2016-11-04 Biogen Ma Inc. Anti-bcma protutijela
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
CN110066339A (zh) 2010-04-20 2019-07-30 根马布股份公司 含异二聚体抗体fc的蛋白及其制备方法
EP2569337A1 (fr) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Protéines hétérodimériques et leurs procédés de production et de purification
EP2420253A1 (fr) 2010-08-20 2012-02-22 Leadartis, S.L. Synthèse de molécules polyvalentes et multifonctionnelles avec un domaine de trimérisation de collagène XV
RU2604490C2 (ru) 2010-11-05 2016-12-10 Займворкс Инк. ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
EP2640750A1 (fr) 2010-11-16 2013-09-25 Boehringer Ingelheim International GmbH Agents et méthodes de traitement de maladies qui sont corrélées à une expression de bcma
AR085934A1 (es) 2011-04-08 2013-11-06 Ab Science Tratamiento de mieloma multiple con masitinib
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
SG11201401422VA (en) 2011-10-27 2014-09-26 Genmab As Production of heterodimeric proteins
KR102052774B1 (ko) 2011-11-04 2019-12-04 자임워크스 인코포레이티드 Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
PL2794905T3 (pl) 2011-12-20 2020-11-02 Medimmune, Llc Zmodyfikowane polipeptydy dla rusztowań przeciwciał dwuswoistych
ES2743399T3 (es) 2012-04-20 2020-02-19 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
UA118255C2 (uk) 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
PT2931030T (pt) 2012-12-14 2020-08-03 Open Monoclonal Tech Inc Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem
PL2953972T3 (pl) 2013-02-05 2021-03-08 Engmab Sàrl Metoda wyboru przeciwciał przeciwko bcma
HK1221908A1 (zh) 2013-04-29 2017-06-16 Adimab, Llc 多特异(polyspecificity)试剂，其制备方法和用途
ES2825625T3 (es) 2013-10-31 2021-05-17 Sanofi Sa Anticuerpos anti-CD38 específicos para tratar cánceres humanos
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
WO2015142675A2 (fr) * 2014-03-15 2015-09-24 Novartis Ag Traitement du cancer au moyen d'un récepteur antigénique chimérique
US11505605B2 (en) 2014-05-13 2022-11-22 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
RS60305B1 (sr) 2014-09-05 2020-07-31 Janssen Pharmaceutica Nv Agensi koji vezuju cd123 i njihove upotrebe
SG10201913937QA (en) * 2014-12-05 2020-03-30 Memorial Sloan Kettering Cancer Center Antibodies targeting g-protein coupled receptor and methods of use
RS62870B1 (sr) 2014-12-05 2022-02-28 Memorial Sloan Kettering Cancer Center Himerni antigenski receptori sa ciljanim delovanjem na receptore spregnute sa g-proteinom i njihove upotrebe
LT3303396T (lt) * 2015-05-29 2023-01-10 Bristol-Myers Squibb Company Antikūnai prieš ox40 ir jų panaudojimo būdai
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
PT3337824T (pt) * 2015-08-17 2020-09-10 Janssen Pharmaceutica Nv Anticorpos anti-bcma, moléculas de ligação a antigénio biespecíficas que ligam bcma e cd3, e suas utilizações
PL3827845T3 (pl) 2015-11-03 2022-07-11 Janssen Biotech, Inc. Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania
TWI797073B (zh) 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 包含雙特異性抗體建構物之醫藥組合物
TWI781108B (zh) * 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
US11214853B2 (en) 2016-08-22 2022-01-04 Sumitomo Electric Industries, Ltd. Hard material and cutting tool
WO2018060301A1 (fr) 2016-09-30 2018-04-05 F. Hoffmann-La Roche Ag Anticorps bispécifiques dirigés contre cd3
US11124577B2 (en) 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
SG11201907321TA (en) 2017-02-07 2019-09-27 Daiichi Sankyo Co Ltd Anti-gprc5d antibody and molecule comprising the antibody
WO2018187215A1 (fr) 2017-04-03 2018-10-11 Merrimack Pharmaceuticals, Inc. Molécules bispécifiques à titre d'agoniste de 4-1bb
MA50185A (fr) 2017-09-22 2020-07-29 Wuxi Biologics Ireland Ltd Nouveaux complexes polypeptidiques cd3/cd19 bispécifiques
AU2019270624B2 (en) 2018-05-16 2024-05-02 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
US20240076376A1 (en) * 2022-08-23 2024-03-07 Janssen Biotech, Inc. Approved products for the treatment of multiple myeloma

Also Published As

Publication number Publication date
JP7749643B2 (ja) 2025-10-06
US20240101697A1 (en) 2024-03-28
IL278667B1 (en) 2025-11-01
MX2024013523A (es) 2024-12-06
US20200190205A1 (en) 2020-06-18
AU2019270624B2 (en) 2024-05-02
UY38235A (es) 2019-11-29
DOP2020000209A (es) 2021-09-30
MY203469A (en) 2024-06-28
PH12020551932A1 (en) 2021-06-21
CN120285175A (zh) 2025-07-11
JP2024026204A (ja) 2024-02-28
JP2024059805A (ja) 2024-05-01
AU2019270624A1 (en) 2020-11-26
CL2024001607A1 (es) 2024-11-22
SG11202010977QA (en) 2020-12-30
CN112368019B (zh) 2025-03-18
NZ769788A (en) 2024-05-31
WO2019220369A3 (fr) 2019-12-26
MY205856A (en) 2024-11-15
MX2024013526A (es) 2024-12-06
JOP20200292A1 (ar) 2020-11-15
CA3100157A1 (fr) 2019-11-21
CA3100118A1 (fr) 2019-11-21
JP7444790B2 (ja) 2024-03-06
MA52640A (fr) 2021-03-24
UY38236A (es) 2019-11-29
TW202438109A (zh) 2024-10-01
JP2021526512A (ja) 2021-10-07
EP3793599A1 (fr) 2021-03-24
AU2019270623B2 (en) 2023-09-07
BR112020023264A2 (pt) 2021-02-23
US12065500B2 (en) 2024-08-20
US12012461B2 (en) 2024-06-18
CL2021002267A1 (es) 2022-04-01
WO2019220368A1 (fr) 2019-11-21
US20240301083A1 (en) 2024-09-12
AU2023274132A1 (en) 2023-12-21
AU2024202300A1 (en) 2024-05-02
US20190352421A1 (en) 2019-11-21
IL278667A (fr) 2021-01-31
SG11202011306TA (en) 2020-12-30
TW202430571A (zh) 2024-08-01
KR20220080044A (ko) 2022-06-14
WO2019220369A2 (fr) 2019-11-21
TW202012442A (zh) 2020-04-01
IL324145A (en) 2025-12-01
JP7395508B2 (ja) 2023-12-11
PH12020551908A1 (en) 2021-06-14
TW202016132A (zh) 2020-05-01
CL2020002945A1 (es) 2021-03-26
AU2019270623A1 (en) 2020-12-03
CN112368019A (zh) 2021-02-12
EP3793606A2 (fr) 2021-03-24
MX2020012270A (es) 2021-04-28
KR20210011002A (ko) 2021-01-29
JP2021526136A (ja) 2021-09-30
BR112020023187A2 (pt) 2021-04-20
MX2024013525A (es) 2024-12-06
MX2020012286A (es) 2021-04-28
NZ769968A (en) 2024-07-05
CN113164588A (zh) 2021-07-23
EP3793606A4 (fr) 2022-08-31

Similar Documents

Publication Publication Date Title
MA52632A (fr) Anticorps bispécifiques bcma/cd3 et gprdc5d/cd3 aux fins d'utilisation dans le traitement du cancer
MA54609A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA54608A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
EP3887528A4 (fr) Constructions plasmidiques pour le traitement du cancer et leurs procédés d'utilisation
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA52232A (fr) Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer
MA47208A (fr) Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1
MA56050A (fr) Inhibiteurs hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA50956A (fr) Anticorps anti-cd137 et procédés d'utilisation correspondants
MA50082A (fr) Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer
MA43658A (fr) Anticorps anti-ror1, anticorps bispécifiques ror1 x cd3, et leurs procédés d'utilisation
EP3793600A4 (fr) Composition d'anticorps bispécifiques et procédé d'utilisation associé
EP4013512C0 (fr) Anticorps bispécifiques contre ceacam5 et cd3
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA52657A (fr) Anticorps spécifiques d'axl pour le traitement du cancer
EP3796920A4 (fr) Compositions d'arnt/pré-miarn et leur utilisation dans le traitement du cancer
EP3436476A4 (fr) Anticorps anti-ryk et leurs procédés d'utilisation
EP3731867A4 (fr) Anticorps anti-lrp5/6 et leurs procédés d'utilisation
EP3830128A4 (fr) Anticorps anti-mica/b qui bloquent l'élimination de mica/b et procédés d'utilisation
EP3710589A4 (fr) Anticorps anti-c1s et procédés d'utilisation
MA52971A (fr) Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle
EP3937980A4 (fr) Miarn modifiés et leur utilisation dans le traitement du cancer
MA53328A (fr) Anticorps anti-siglec-5 et leurs procédés d'utilisation
EP3953385A4 (fr) Anticorps cd19 et leurs procédés d'utilisation
EP3873941A4 (fr) Anticorps anti-pd-1 humain et procédés d'utilisation associés